JPH09507050A - 抗新生物剤としての酪酸、酪酸塩、および誘導体の生理学的に安定な組成物 - Google Patents
抗新生物剤としての酪酸、酪酸塩、および誘導体の生理学的に安定な組成物Info
- Publication number
- JPH09507050A JPH09507050A JP7512663A JP51266395A JPH09507050A JP H09507050 A JPH09507050 A JP H09507050A JP 7512663 A JP7512663 A JP 7512663A JP 51266395 A JP51266395 A JP 51266395A JP H09507050 A JPH09507050 A JP H09507050A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- butyrate
- composition
- patient
- butyric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.患者における新生物形成異常を処置または予防するための方法であって、以 下の工程: a) 生理学的に安定な酪酸塩または8個未満の炭素からなる酪酸誘導体、および 薬学的に受容し得るキャリアーを含む、治療上または予防上効果的な組成物を提 供する工程であって、ここで該組成物が本質的にナトリウムを含まない工程;お よび b) 該組成物を該患者に投与する工程、 を包含する方法。 2.前記新生物形成異常が、白血病、リンパ種、肉腫、ガン、神経細胞腫瘍、扁 平上皮ガン、生殖細胞腫瘍、未分化腫瘍、精上皮腫、メラノーマ、神経芽腫、混 合細胞腫瘍、転移性新生物形成、病原感染による新生物形成および他の悪性腫瘍 からなる群より選択される、請求項1に記載の方法。 3.前記患者がヒトである、請求項1に記載の方法。 4.前記安定性が約15分以上である、請求項1に記載の方法。 5.前記安定性が約2時間以上である、請求項1に記載の方法。 6.前記安定性が約4時間以上である、請求項1に記載の方法。 7.前記薬剤の安定性が、インビボ半減期、血清半減期、または処置終了後ある いは該薬剤の血清レベルが半分以上減少した後も継続する生物学的効果によって 測定される、請求項1に記載の方法。 8.前記生物学的効果が、症状の改善、新生物細胞のサイズ、量または数の減 少、分化の誘導または遺伝子発現における変化である、請求項7に記載の方法。 9.前記症状が、痛み、疲労、出血、熱、体重の減少、寝汗、嘔吐、腸習性の変 化、腫脹および精神的失見当からなる群より選択される、請求項8に記載の方法 。 10.前記変化する発現する遺伝子が、多剤耐性タンパク質、インターロイキン レセプター、成長因子レセプター、腫瘍特異抗原または主要組織適合性抗原をコ ードする、請求項8に記載の方法。 11.前記酪酸誘導体がイソブチルアミドである、請求項1に記載の方法。 12.前記薬学的に受容し得るキャリアーが、水、エタノール、生理食塩水、グ リセロール、多糖およびオイルからなる群より選択される、請求項1に記載のの 方法。 13.前記組成物が、非経口的に、舌下に、直腸的に、経腸的に、肺吸収により または局所的な適用よって投与される、請求項1に記載の方法。 14.前記非経口投与が、静脈内注射、皮下注射、筋肉注射、動脈内注射、包膜 内注射、腹腔内注射または前記新生物部位への直接注射による、請求項13に記 載の方法。 15.複数の生理学的に安定な酪酸塩および/または8個未満の炭素からなる酪 酸誘導体が前記患者に投与される、請求項1に記載の方法。 16.新生物細胞の分化を誘導することによって、患者における新生物形成異常 を処置または予防するための方法であって、以下の工程: a) 生理学的に安定な酪酸塩または8個未満の炭素からなる酪酸誘導体、および 薬学的に受容し得るキャリアーを含む、治療上または予防上効果的な組成物を提 供する工程;および b) 該組成物を該患者に投与して該新生物細胞の分化を誘導する工程、 を包含する方法。 17.前記分化が、前記新生物形成のサイズまたは量の減少、主要組織適合性抗 原または分化抗原の増加した発現または減少した発現、減少したDNA複製、また は減少した細胞***によって決定される、請求項16に記載の方法。 18.前記分化抗原が、成長因子レセプター、インターロイキンおよび他のサイ トカインレセプターからなる群より選択される細胞表面レセプター、および主要 組織適合性抗原からなる群より選択される、請求項17に記載の方法。 19.前記分化抗原が、インターロイキン-2レセプターおよび上皮増殖因子レセ プターからなる群より選択される、請求項17に記載の方法。 20.複数の、1つまたはそれ以上の生理学的に安定な酪酸塩、および/または 8個未満の炭素からなる1つまたはそれ以上の酪酸誘導体が、前記患者に投与さ れる、請求項16に記載の方法。 21.前記複数状態が、アルギニンブチレートおよびイソブチルアミドを包む、 請求項20に記載の方法。 22.患者における新生物形成異常を処置するための方法であって、以下の工程 : a) イソブチルアミドを含む、治療上効果的な組成物を調製する工程;および b) 該組成物を該患者に投与する工程、 を包含する方法。 23.患者における新生物形成異常を、該患者の新生物細胞の抗原発現を誘導す ることによって処置するための方法であって、以下の方法: a) 生理学的に安定な酪酸塩または酪酸誘導体を含む、治療上効果的な組成物を 提供する工程;および b) 該組成物を該患者に投与して、該抗原の発現を誘導する工程、 を包含する方法。 24.前記発現する抗原が、腫瘍特異抗原、多剤耐性タンパク質、細胞表面レセ プターおよび主要組織適合性抗原からなる群より選択される、請求項23に記載 の方法。 25.前記細胞表面レセプターが、インターロイキン-2レセプターまたは上皮増 殖因子レセプターである、請求項24に記載の方法。 26.化学療法剤を前記患者に投与する工程をさらに包含する、請求項24に記 載の方法。 27.前記化学療法薬剤が、アルキル化剤、プリンおよびピリミジンアナログ、 ビンカおよびビンカ様アルカロイド、エトポシドおよびエトポシド様薬物、抗生 物質、コルチコステロイド、ニトロソ尿素、代謝拮抗物質、プラチナをベースに した細胞傷害性薬物、ホルモン性アンタゴニスト、抗アンドロゲンおよび抗エス トロゲンからなる群より選択される、請求項26に記載の方法。 28.前記抗生物質が、抗菌剤、抗真菌剤または抗ウイルス剤である、請求項2 7に記載の方法。 29.前記化学療法剤が、タモキシフェン、ドキソルビシン、L-アスパラギナー ゼ、ダカルバジン、アムサクリン、プロカルバジン、ヘキサメチルメラミンおよ びミトキサントロンからなる群より選択される、請求項26に記載の方法。 30.患者の「創傷」を処置するための方法であって、以下の工程: a) 生理学的に安定な酪酸塩または6個未満の炭素からなる酪酸誘導体を含む、 治療上効果的な組成物を提供する工程;および b) 該組成物を該患者に投与する工程、 を包含する方法。 31.前記組成物がアルギニンブチレートを含有する、請求項30に記載の方法 。 32.前記アルギニンブチレートが注射によって投与される、請求項31に記載 の方法。 33.前記組成物がイソブチルアミドを含有する、請求項30に記載の方法。 34.前記イソブチルアミドが経口的に投与される、請求項33に記載の方法。 35.患者における胃腸異常を処置または予防するための方法であって、以下の 工程: a) 生理学的に安定な酪酸塩または酪酸誘導体を含む、治療上または予防上効果 的な組成物を提供する工程;および b) 該組成物を該患者に投与する工程、 を包含する方法。 36.前記胃腸異常が、大腸炎、炎症性腸疾患、クローン病および潰瘍性大腸炎 からなる群より選択される、請求項35に記載の方法。 37.前記組成物が、経口的にまたは浣腸剤として投与される形態である、請求 項35に記載の方法。 38.前記酪酸塩がアルギニンブチレートである、請求項35に記載の方法。 39.前記酪酸誘導体がイソブチルアミドである、請求項35に記載の方法。 40.生理学的に安定な酪酸塩または酪酸誘導体、および薬学的に受容し得るキ ャリアーを含む、組成物。 41.前記薬学的に受容し得るキャリアーが、水、エタノール、生理食塩水、グ リセロール、多糖およびオイルからなる群より選択される、請求項40に記載の 組成物。 42.サイトカインまたは化学療法剤をさらに含む、請求項40に記載の組成物 。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14290893A | 1993-10-29 | 1993-10-29 | |
US08/142,908 | 1993-10-29 | ||
PCT/US1994/011565 WO1995011699A1 (en) | 1993-10-29 | 1994-10-13 | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007059287A Division JP2007145865A (ja) | 1993-10-29 | 2007-03-08 | 抗新生物剤としての酪酸、酪酸塩、および誘導体の生理学的に安定な組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09507050A true JPH09507050A (ja) | 1997-07-15 |
JP3971454B2 JP3971454B2 (ja) | 2007-09-05 |
Family
ID=22501771
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51266395A Expired - Fee Related JP3971454B2 (ja) | 1993-10-29 | 1994-10-13 | 抗新生物剤としての酪酸、酪酸塩、および誘導体の生理学的に安定な組成物 |
JP2007059287A Withdrawn JP2007145865A (ja) | 1993-10-29 | 2007-03-08 | 抗新生物剤としての酪酸、酪酸塩、および誘導体の生理学的に安定な組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007059287A Withdrawn JP2007145865A (ja) | 1993-10-29 | 2007-03-08 | 抗新生物剤としての酪酸、酪酸塩、および誘導体の生理学的に安定な組成物 |
Country Status (7)
Country | Link |
---|---|
US (2) | US5858365A (ja) |
EP (2) | EP1736152A3 (ja) |
JP (2) | JP3971454B2 (ja) |
AU (1) | AU696167B2 (ja) |
CA (1) | CA2174737C (ja) |
RO (1) | RO115498B1 (ja) |
WO (1) | WO1995011699A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012529497A (ja) * | 2009-06-09 | 2012-11-22 | シーマス リミテッド | ハロゲン化脂肪族カルボン酸、そのオリゴマーおよび/またはポリマー、ならびに、表面的および内部の新生物を失活化することにおけるそれらの使用 |
JP2012236842A (ja) * | 2003-07-02 | 2012-12-06 | Genentech Inc | Trp−p8活性化合物と治療的処置方法 |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7910624B1 (en) | 1995-03-03 | 2011-03-22 | The Trustees Of Boston University | Compositions for the treatment of blood disorders |
JP3971454B2 (ja) * | 1993-10-29 | 2007-09-05 | ザ トラスティーズ オブ ボストン ユニバーシティ | 抗新生物剤としての酪酸、酪酸塩、および誘導体の生理学的に安定な組成物 |
US5700640A (en) * | 1994-09-16 | 1997-12-23 | Basf Aktiengesellschaft | Inducers of gamma globin gene expression and screening assays therefor |
US5763415A (en) * | 1995-08-03 | 1998-06-09 | John Hopkins University School Of Medicine | Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer |
US5939456A (en) * | 1996-07-26 | 1999-08-17 | Perrine; Susan P. | Pulsed administration of compositions for the treatment of blood disorders |
EP0969869A2 (en) * | 1996-07-26 | 2000-01-12 | Susan P. Perrine | Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders |
US6403647B1 (en) | 1996-07-26 | 2002-06-11 | Susan P. Perrine | Pulsed administration of compositions for the treatment of blood disorders |
US6197743B1 (en) * | 1996-07-26 | 2001-03-06 | The Trustees Of Boston University | Compositions and methods for the treatment of viral disorders |
AUPO255996A0 (en) * | 1996-09-23 | 1996-10-17 | Northern Sydney Area Health Service | Cell inhibition |
US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
US7192450B2 (en) * | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US6822267B1 (en) * | 1997-08-20 | 2004-11-23 | Advantest Corporation | Signal transmission circuit, CMOS semiconductor device, and circuit board |
WO1999040883A2 (en) | 1998-02-11 | 1999-08-19 | Faller Douglas V | Compositions and methods for the treatment of cystic fibrosis |
US6576420B1 (en) * | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
US7025994B1 (en) | 1999-01-11 | 2006-04-11 | Briskin Robert A | Dietary compounds useful for the reduction of pathological conditions and the promotion of good health |
US6294349B1 (en) | 1999-03-01 | 2001-09-25 | University Of Mississippi Medical Ctr. | Method of diagnosing and monitoring malignant breast carcinomas |
US6518012B1 (en) * | 1999-04-02 | 2003-02-11 | Health Research, Inc. | Method for regulating the expression of MHC antigens and CD40 by inhibitors of histone deacetylation |
US6187822B1 (en) * | 1999-06-11 | 2001-02-13 | University Of Medicine & Dentistry Of Nj | Wound treatment through inhibition of adenosine diphosphate ribosyl transferase |
WO2001078704A2 (en) * | 2000-04-13 | 2001-10-25 | Evans William T | Gaba substrate and the use thereof for treating cognitive and emotional disorders |
EP1170008A1 (en) * | 2000-07-07 | 2002-01-09 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Valproic acid and derivatives thereof as histone deacetylase inhibitors |
US6613356B1 (en) | 2000-10-10 | 2003-09-02 | Victor Vlahakos | Weight loss medication and method |
GB0113697D0 (en) * | 2001-06-06 | 2001-07-25 | Smith & Nephew | Fixation devices for tissue repair |
RU2217196C2 (ru) | 2002-02-28 | 2003-11-27 | Небольсин Владимир Евгеньевич | Способ индукции дифференцировки клеток |
US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7169801B2 (en) | 2003-03-17 | 2007-01-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7875293B2 (en) * | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
WO2007120442A2 (en) * | 2003-07-25 | 2007-10-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
ATE480761T1 (de) | 2003-12-05 | 2010-09-15 | Dexcom Inc | Kalibrationsmethoden für einen kontinuierlich arbeitenden analytsensor |
US20050159470A1 (en) * | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
WO2005066151A2 (en) * | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US7946984B2 (en) | 2004-07-13 | 2011-05-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20060270922A1 (en) | 2004-07-13 | 2006-11-30 | Brauker James H | Analyte sensor |
US7905833B2 (en) * | 2004-07-13 | 2011-03-15 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7655678B2 (en) * | 2004-11-30 | 2010-02-02 | Council of Scientfic & Industrial Research | Pharmaceutical composition for the management of tumors |
WO2006066133A2 (en) * | 2004-12-16 | 2006-06-22 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US8060174B2 (en) * | 2005-04-15 | 2011-11-15 | Dexcom, Inc. | Analyte sensing biointerface |
US7642253B2 (en) * | 2005-05-11 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
AU2006270322A1 (en) * | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
WO2007035755A2 (en) * | 2005-09-19 | 2007-03-29 | Duke University | Methods of treating hematological malignancies |
WO2007084390A2 (en) * | 2006-01-13 | 2007-07-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
ES2745411T3 (es) * | 2006-07-27 | 2020-03-02 | Wang Nai Fang | Compuestos y composiciones de arilsulfanilo para administración de agentes activos |
KR100770440B1 (ko) * | 2006-08-29 | 2007-10-26 | 삼성전기주식회사 | 질화물 반도체 발광소자 |
US20080107743A1 (en) * | 2006-11-02 | 2008-05-08 | Akpharma Inc. | Composition and method for enhancing skin cell growth, proliferation and repair |
EP2152350A4 (en) | 2007-06-08 | 2013-03-27 | Dexcom Inc | INTEGRATED MEDICINE DELIVERY DEVICE FOR USE WITH A CONTINUOUS ANALYZING SUBSTANCE SENSOR |
EP4159114B1 (en) | 2007-10-09 | 2024-04-10 | DexCom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8290559B2 (en) * | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
WO2010105112A1 (en) * | 2009-03-11 | 2010-09-16 | Hemaquest Pharmaceuticals, Inc. | Detection of short-chain fatty acids in biological samples |
GB0911215D0 (en) | 2009-06-29 | 2009-08-12 | Univ Erasmus Medical Ct | Gamma globin therapy |
WO2011038224A1 (en) | 2009-09-24 | 2011-03-31 | Trustees Of Boston University | Methods for treating viral disorders |
WO2011056978A2 (en) | 2009-11-04 | 2011-05-12 | Trustees Of Boston University | S isomers of alpha-methyl hydrocinnamic acid for the treatment of blood disorders |
MA33899B1 (fr) | 2009-12-08 | 2013-01-02 | Hemaquest Pharmaceuticals Inc | Procedes et regimes a faible dose pour des troubles des globules rouges |
WO2011113013A2 (en) | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Methods and compositions for treating viral or virally-induced conditions |
GB201012420D0 (en) | 2010-07-23 | 2010-09-08 | Univ Erasmus Medical Ct | Foetal heamoglobin inhibitor |
US10864184B1 (en) | 2013-11-27 | 2020-12-15 | University Of South Florida | Metabolic therapy for wound healing |
US20150374878A1 (en) | 2014-06-27 | 2015-12-31 | Akeso Biomedical, Inc. | Angiogenic devices for wound care |
RU2017127597A (ru) | 2015-01-23 | 2019-02-25 | Темпл Юнивёрсити-Оф Дзе Коммонвелс Систем Оф Хайе Эдьюкейшен | Применение короткоцепочечных жирных кислот для профилактики рака |
US11065217B2 (en) | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
CN110891982B (zh) | 2017-04-17 | 2023-12-22 | 芝加哥大学 | 向肠道递送短链脂肪酸以用于人体保健和疾病治疗的聚合物材料 |
US20190117131A1 (en) | 2017-10-24 | 2019-04-25 | Dexcom, Inc. | Pre-connected analyte sensors |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US20220226322A1 (en) | 2019-05-31 | 2022-07-21 | Viracta Subsidiary, Inc. | Methods of treating virally associated cancers with histone deacetylase inhibitors |
US11666548B2 (en) | 2020-06-05 | 2023-06-06 | Baxter International Inc. | Parenteral nutrition formulation |
US20220160669A1 (en) | 2020-11-24 | 2022-05-26 | Baxter International Inc. | Parenteral nutrition formulation |
WO2023153861A1 (ko) * | 2022-02-10 | 2023-08-17 | 코아스템켐온 주식회사 | 커큐민 및 진세노사이드를 포함하는 약학 조성물 및 이의 제형 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3471513A (en) * | 1966-11-01 | 1969-10-07 | Searle & Co | 2-(2-carboxyethyl)-5-phenyl-1-pyrrole-butyric acid and congeners |
BE789077A (fr) * | 1971-09-22 | 1973-01-15 | Nitto Boseki Co Ltd | Procede de preparation de derives de pyrimidine |
US4026895A (en) * | 1973-09-08 | 1977-05-31 | Eisai Co., Ltd. | 1,3-Benzodioxol derivatives |
GB1498903A (en) * | 1974-03-25 | 1978-01-25 | Fabre Sa Pierre | Aromatic keto-acids and their derivatives |
FR2300551A2 (fr) * | 1975-02-17 | 1976-09-10 | Fabre Sa Pierre | Nouveaux |
GB1484413A (en) * | 1974-04-18 | 1977-09-01 | Kissei Pharmaceutical | Aromatic amidocarboxylic acid derivatives |
DE2456958A1 (de) * | 1974-12-03 | 1976-06-16 | Basf Ag | 3-(p-biphenylyl)-butyronitril und seine anwendung als arzneimittel |
US4031243A (en) * | 1975-07-03 | 1977-06-21 | Juste, S.A. Quimico-Farmaceutica | 2-(4-Isobutyl phenyl)butyric acid, salts thereof, and pharmaceutical compositions containing the same |
GB1518764A (en) * | 1976-03-17 | 1978-07-26 | Soc D Etudes Prod Chimique | Isobutyramides their preparation and therapeutic composititions containing them |
US4176193A (en) * | 1977-03-17 | 1979-11-27 | Societe D'etudes De Produits Chimiques | Therapeutic isobutyramides |
US4732914A (en) * | 1978-02-13 | 1988-03-22 | The Upjohn Company | Prostacyclin analogs |
US4234599A (en) * | 1978-10-04 | 1980-11-18 | Scott Eugene J Van | Treatment of skin keratoses with α-hydroxy acids and related compounds |
FR2508797B1 (fr) * | 1981-07-03 | 1986-03-14 | Charles Chany | Medicament comprenant le produit de la reaction d'un acide carboxylique en c1 a c6 sur un amino-acide basique |
US4704402A (en) * | 1982-06-12 | 1987-11-03 | University Of Pittsburgh | Method of treating sickle cell anemia |
GB2126082A (en) * | 1982-08-12 | 1984-03-21 | Heinrich Schulze | Pharmaceutical preparations having analgetic and cytostatic activity |
US4894364A (en) * | 1983-10-26 | 1990-01-16 | Greer Sheldon B | Method and materials for sensitizing neoplastic tissue to radiation |
US4851229A (en) * | 1983-12-01 | 1989-07-25 | Alza Corporation | Composition comprising a therapeutic agent and a modulating agent |
US4671901A (en) * | 1984-01-26 | 1987-06-09 | Oral-D | Orally effective ion chelators |
CA1249968A (en) * | 1984-04-05 | 1989-02-14 | Kazuo Kigasawa | Ointment base |
US4747825A (en) * | 1984-06-29 | 1988-05-31 | Ferring Laboratories, Inc. | Apparatus and methodology for pulsed administration of growth promoting agents |
US4613616A (en) * | 1984-07-20 | 1986-09-23 | Research Corporation | Polymeric iron chelators |
JPS61155358A (ja) * | 1984-12-21 | 1986-07-15 | Suntory Ltd | ジアリール酪酸誘導体 |
US4735967A (en) * | 1985-05-28 | 1988-04-05 | Neesby Torben E | Method for desensitizing the gastrointestinal tract from food allergies |
DE3534743A1 (de) * | 1985-09-28 | 1987-04-02 | Beiersdorf Ag | Hydrocortisondiester enthaltende o/w-creme |
EP0224599A1 (en) * | 1985-11-06 | 1987-06-10 | National Patent Development Corporation | Chemical solution useful in the treatment of teeth |
GB8607683D0 (en) * | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
US4751244A (en) * | 1986-04-04 | 1988-06-14 | Merck & Co., Inc. | Compounds useful in treating sickle cell anemia |
US4731381A (en) * | 1986-04-04 | 1988-03-15 | Merck & Co., Inc. | Method of treating a person for sickle cell anemia |
US4699926A (en) * | 1986-04-04 | 1987-10-13 | Merck & Co., Inc. | Compounds useful in treating sickle cell anemia |
US4948592A (en) * | 1986-05-09 | 1990-08-14 | Alza Corporation | Pulsed drug delivery |
US4723958A (en) * | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
US4822821A (en) * | 1986-10-10 | 1989-04-18 | Children's Hospital Medical Center Of Northern California | Method for augmenting fetal hemoglobin |
US5025029A (en) * | 1986-10-10 | 1991-06-18 | Children's Hospital Medical Center Of Northern California | Method for augmenting fetal hemoglobin |
US4965251A (en) * | 1987-04-03 | 1990-10-23 | The Board Of Regents Of The University Of Washington | Pulse treatment of hemoglobinopathies with erythropoietin |
US4820711A (en) * | 1987-05-15 | 1989-04-11 | Pearlman Dale L | Method for treating actinic keratosis with cytotoxic agents |
US4849426A (en) * | 1987-05-15 | 1989-07-18 | Pearlman Dale L | Method for treating actinic keratosis with cytotoxic agents |
US4853388A (en) * | 1987-05-15 | 1989-08-01 | Pearlman Dale L | Method for treating psoriasis with cytotoxic agents |
FR2633929B2 (fr) * | 1987-09-25 | 1995-05-24 | Picardie Universite | Derives non toxiques de l'acide n-butyrique, presentant des actions therapeutiques retardees |
US5032507A (en) * | 1987-11-13 | 1991-07-16 | The Salk Institute For Biological Studies | Potentiation of erythropoiesis |
DE3742222A1 (de) * | 1987-12-12 | 1989-06-22 | Basf Ag | (2r)-aryloxy-3-n-butyroyloxy-propan-2-ole |
US4880624A (en) * | 1988-03-18 | 1989-11-14 | The Board Of Trustees Of The University Of Illinois | Volatile attractants for diabrotica species |
US4958592A (en) * | 1988-08-22 | 1990-09-25 | General Electric Company | Resistance heater for diamond production by CVD |
US4925873A (en) * | 1988-09-01 | 1990-05-15 | E. R. Squibb & Sons, Inc. | Method of treating skin injuries using thromboxane A2 receptor antagonists |
US4997815A (en) * | 1988-11-01 | 1991-03-05 | Children's Hospital Medical Center Of Northern California | Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin |
US5137734A (en) * | 1989-03-22 | 1992-08-11 | Dana Farber Cancer Institute | Angiogenic monoglycerides |
US5039703A (en) * | 1989-11-16 | 1991-08-13 | Breuer Richard I | Method for treating inflammatory bowel disorders |
GB8929070D0 (en) * | 1989-12-22 | 1990-02-28 | Fujisawa Pharmaceutical Co | Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same |
US5674898A (en) * | 1990-03-05 | 1997-10-07 | Genzyme Corporation | Methods and therapeutic compositions for treating cystic fibrosis |
US5258367A (en) * | 1990-06-29 | 1993-11-02 | University Of Florida | Uteroferrin and rose proteins for stimulating hematopoietic cells |
SE9002732D0 (sv) * | 1990-08-24 | 1990-08-24 | Kabivitrum Ab | Product containing growth factor |
US5216004A (en) * | 1990-09-13 | 1993-06-01 | Children's Hospital Medical Center Of North California | Method for preventing malaria |
US5100647A (en) * | 1990-10-02 | 1992-03-31 | The Trustees Of The University Of Pennsylvania | Method and formulations for the therapy of cystic fibrosis, Bartter's syndrome and secretory diarrheas, and for diuretic treatment |
US5674912A (en) * | 1991-03-01 | 1997-10-07 | Warner-Lambert Company | Sunscreen-wound healing compositions and methods for preparing and using same |
US5270458A (en) * | 1991-04-02 | 1993-12-14 | The Trustees Of Princeton University | Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2 |
US5199942A (en) * | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
US5605930A (en) * | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
US5635532A (en) * | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
WO1993015739A1 (en) * | 1992-02-07 | 1993-08-19 | Kaken Pharmaceutical Co., Ltd. | Remedy for wound or hemorrhoid |
CA2090283A1 (en) * | 1992-02-28 | 1993-08-29 | Nobuyuki Hamanaka | Phenoxyacetic acid derivatives |
US7326535B2 (en) * | 1993-09-15 | 2008-02-05 | Ortho Diagnostic Systems Inc. | Immunoreactive peptides from Epstein-Barr virus |
US5366996A (en) * | 1992-12-07 | 1994-11-22 | Elford Howard L | Method of treating hemoglobinopathies |
US5403590A (en) * | 1992-12-21 | 1995-04-04 | New England Deaconess Hospital Corporation | Method of pulsatile drug infusion |
JP3971454B2 (ja) * | 1993-10-29 | 2007-09-05 | ザ トラスティーズ オブ ボストン ユニバーシティ | 抗新生物剤としての酪酸、酪酸塩、および誘導体の生理学的に安定な組成物 |
US7888458B1 (en) * | 1993-11-30 | 2011-02-15 | John B. Harley | Diagnostics and therapy of epstein-barr virus in autoimmune disorders |
US5952314A (en) * | 1994-04-01 | 1999-09-14 | Demichele; Stephen Joseph | Nutritional product for a person having ulcerative colitis |
US5780451A (en) * | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
US6011000A (en) * | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
US5883123A (en) * | 1995-10-06 | 1999-03-16 | Vertex Pharmaceuticals, Inc. | Butyrate prodrugs derived from lactic acid |
US5912269A (en) * | 1996-04-30 | 1999-06-15 | Vertex Pharmaceuticals, Inc. | Butyrate prodrugs derived from lactic acid |
US5763488A (en) * | 1995-10-30 | 1998-06-09 | Vertex Pharmaceuticals Incorporated | Methods and compositions using butyrate esters of threitol |
US5846528A (en) * | 1996-01-18 | 1998-12-08 | Avigen, Inc. | Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence |
US6197743B1 (en) * | 1996-07-26 | 2001-03-06 | The Trustees Of Boston University | Compositions and methods for the treatment of viral disorders |
US5939456A (en) * | 1996-07-26 | 1999-08-17 | Perrine; Susan P. | Pulsed administration of compositions for the treatment of blood disorders |
US6403647B1 (en) * | 1996-07-26 | 2002-06-11 | Susan P. Perrine | Pulsed administration of compositions for the treatment of blood disorders |
US6043389A (en) * | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
US6030961A (en) * | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
US5932545A (en) * | 1997-03-17 | 1999-08-03 | Abbott Laboratories | Antiangiogenic drug to treat cancer, arthritis and retinopathy |
US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
WO1999040883A2 (en) * | 1998-02-11 | 1999-08-19 | Faller Douglas V | Compositions and methods for the treatment of cystic fibrosis |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
US20060069060A1 (en) * | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
FR2881746B1 (fr) * | 2005-02-07 | 2007-04-13 | Centre Nat Rech Scient | Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications |
WO2008028193A2 (en) * | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
-
1994
- 1994-10-13 JP JP51266395A patent/JP3971454B2/ja not_active Expired - Fee Related
- 1994-10-13 WO PCT/US1994/011565 patent/WO1995011699A1/en not_active Application Discontinuation
- 1994-10-13 EP EP06021311A patent/EP1736152A3/en not_active Withdrawn
- 1994-10-13 EP EP94930734A patent/EP0731712A4/en not_active Withdrawn
- 1994-10-13 AU AU79767/94A patent/AU696167B2/en not_active Ceased
- 1994-10-13 RO RO96-00889A patent/RO115498B1/ro unknown
- 1994-10-13 CA CA002174737A patent/CA2174737C/en not_active Expired - Fee Related
-
1995
- 1995-06-07 US US08/473,957 patent/US5858365A/en not_active Expired - Lifetime
-
2007
- 2007-03-08 JP JP2007059287A patent/JP2007145865A/ja not_active Withdrawn
-
2008
- 2008-08-28 US US12/200,588 patent/US20090082444A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012236842A (ja) * | 2003-07-02 | 2012-12-06 | Genentech Inc | Trp−p8活性化合物と治療的処置方法 |
JP2012529497A (ja) * | 2009-06-09 | 2012-11-22 | シーマス リミテッド | ハロゲン化脂肪族カルボン酸、そのオリゴマーおよび/またはポリマー、ならびに、表面的および内部の新生物を失活化することにおけるそれらの使用 |
Also Published As
Publication number | Publication date |
---|---|
AU696167B2 (en) | 1998-09-03 |
CA2174737C (en) | 2008-04-22 |
EP1736152A3 (en) | 2009-10-07 |
CA2174737A1 (en) | 1995-05-04 |
RO115498B1 (ro) | 2000-03-30 |
EP1736152A2 (en) | 2006-12-27 |
EP0731712A4 (en) | 2005-11-09 |
AU7976794A (en) | 1995-05-22 |
EP0731712A1 (en) | 1996-09-18 |
US5858365A (en) | 1999-01-12 |
US20090082444A1 (en) | 2009-03-26 |
JP2007145865A (ja) | 2007-06-14 |
WO1995011699A1 (en) | 1995-05-04 |
JP3971454B2 (ja) | 2007-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3971454B2 (ja) | 抗新生物剤としての酪酸、酪酸塩、および誘導体の生理学的に安定な組成物 | |
US8846039B2 (en) | Method for ameliorating pruritus | |
Rephaeli et al. | Derivatives of butyric acid as potential anti‐neoplastic agents | |
AU2002311985B9 (en) | Methods for inhibiting angiogenesis | |
US20220218652A1 (en) | Methods of treating cytokine release syndrome | |
US20100035989A1 (en) | Compositions and methods for the treatment of mucositis | |
JP2001518935A (ja) | 抗癌剤としてのジ―アリールエーテル類及びそれらの誘導体 | |
EP2033635B1 (en) | Use of phenylbutyric acid or salts thereof for treating pruritus | |
JP2007500673A (ja) | ポリアクリル酸塩および化学誘引物質を含む粘膜付着性組成物 | |
CN109152758A (zh) | 使用依氟鸟氨酸及其类似物和衍生物来治疗包括胶质瘤的癌症的组合物和方法 | |
JP3041232B2 (ja) | 癌転移抑制剤 | |
JP2018513130A (ja) | Hsp90阻害ペプチド結合体及びその腫瘍治療における応用 | |
AU677786B2 (en) | Lysozyme dimer and compositions containing the same | |
Krahenbuhl et al. | Effects of Corynebacterium parvum treatment and Toxoplasma gondii infection on macrophage-mediated cytostasis of tumour target cells. | |
RU2741577C2 (ru) | Сублингвальное или буккальное введение dim для лечения заболеваний кожи | |
US20040048808A1 (en) | Methods for inhibiting angiogenesis | |
Engelman et al. | Calories, parity, and prolactin influence mammary epithelial kinetics and differentiation and alter mouse mammary tumor risk | |
KR102122970B1 (ko) | 금제제를 유효성분으로 포함하는 파골세포 분화 억제용 조성물 | |
CN115300507B (zh) | I-brd9作为arih1激动剂的用途 | |
KR102349013B1 (ko) | 멜라토닌을 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
US11464762B2 (en) | Carcinogenesis inhibitor | |
KR20230127990A (ko) | 암 예방에서 단쇄 지방산의 용도 | |
CA3219872A1 (en) | Compounds inhibiting the synergistic carsinogenic effect of heavy metals in the presence of other carcinogens for use in the treatment of cancer | |
US20040048807A1 (en) | Angiogenesis inhibitors | |
JP2022534412A (ja) | プロカスパーゼ‐3の活性化及びがんの治療のための免疫療法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050628 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050921 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060307 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060606 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060724 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060906 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20061212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070308 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070426 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070510 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070608 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110615 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |